New treatment paradigms in advanced stage cervical cancer

Cervical cancer is still a global health problem, being the fourth most common cancer in incidence and mortality in women worldwide. Most of the cases are associated with HPV 16/18 infection. In the past, therapeutic options for advanced stage disease were mournful compared to other fields of oncology. In recent years the treatment paradigms of cervical cancer have changed rapidly. The introduction of immune checkpoint inhibitors has revolutionized the treatment landscape of this disease achieving new standards of overall survival in both the post-platinum and frontline settings. The unconventional antibody drug conjugates demonstrated activity in pre-treated patients as well giving options to those patients who are ineligible to or progressed on ICI treatment. Ongoing trials promise further developments for these patients.